A novel event-free survival endpoint in locally advanced pancreatic cancer by Pascal Hammel, Ewa Carrier, Mairead Carney, Mark Eisner, Thomas Fleming

“…It is an analog to disease-free survival (DFS) endpoint in the adjuvant setting applied to the neoadjuvant setting and may be a valuable surrogate endpoint for this patient population.…”
Get full text

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine? by Moritz Fürstenau, Nisha De Silva, Barbara Eichhorst, Michael Hallek

“…While the relevance of MRD assessment as a surrogate endpoint in clinical trials is largely undisputed, its role in routine clinical practice has not yet been well defined. …”
Get full text

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials by Keith D. Amos, Barbara Adamo, Carey K. Anders

“…In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. …”
Get full text

Improving the quality of life and improving prognosis in cardiology: two sides of the same coin. Overview of the satellite symposium by I. A. Belokrylov

“…Nedoshivin «Quality of life of a patient with stable ischemic disease: a surrogate endpoint or the most important goal of treatment?» …”
Get full text

Economic challenges of oncological diseases’ pharmacotherapy by E. A. Ushkalova, S. K. Zyryanov, I. A. Gopienko

“…At the same time, many innovative medications have only minor advantages over cheaper old medications because they are registered based on the data on the achievement of the surrogate endpoint – extension of progression-free survival. …”
Get full text

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? by Robert B. Cameron, Jacobi B. Hines, Valter Torri, Luca Porcu, Jessica Donington, Christine M. Bestvina, Everett Vokes, James M. Dolezal, Alessandra Esposito, Marina C. Garassino

“…Considering the long time required to conduct trials, it is important to identify optimal endpoints and discover surrogate endpoints for survival that can help guide ongoing clinical research. …”
Get full text

Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains by Akira Matsumori

“…FLCs could be a surrogate endpoint in the management of diabetes. In this review, the role of inflammation in the pathogenesis of diabetes, as well as the novel inflammatory biomarkers of FLCs for the management of diabetes, are discussed.…”
Get full text

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies by Coresh, J, Heerspink, H, Sang, Y, Woodward, M, al., E

“…<strong>Background</strong> Change in albuminuria as a surrogate endpoint for progression of chronic kidney disease is strongly supported by biological plausibility, but empirical evidence to support its validity in epidemiological studies is lacking. …”

Novel biomarkers for diabetic kidney disease by Chan-Young Jung, Tae-Hyun Yoo

“…To identify those at high risk of developing DKD and disease progression at an early stage, extensive research has been ongoing in the search for prognostic and surrogate endpoint biomarkers for DKD. Although biomarkers are not used routinely in clinical practice or prospective clinical trials, many biomarkers have been developed to improve the early identification and prognostication of patients with DKD. …”
Get full text

Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon? by Fokas, E, Liersch, T, Fietkau, R, Hohenberger, W, Hess, C, Becker, H, Sauer, R, Wittekind, C, Rödel, C

“…Downstaging after neoadjuvant treatment is increasingly used as a prognostic factor and surrogate endpoint in clinical trials. However, in recent trials of neoadjuvant 5-fluorouracil-based chemoradiotherapy for rectal cancer, downstaging did not translate into a benefit with regard to either disease-free survival (DFS) or overall survival. …”

Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer by Matthew Sean Peach, Timothy N. Showalter, Nitin Ohri

“…Acute gastrointestinal toxicity could also be explored as a surrogate endpoint for late effects in prospective trials.…”
Get full text

Highly sensitive quantitative real-time PCR for the detection of Plasmodium liver-stage parasite burden following low-dose sporozoite challenge. by Sophie Schussek, Penny L Groves, Simon H Apte, Denise L Doolan

“…Typically, the onset of blood stage parasitaemia is used as a surrogate endpoint to estimate the efficacy of vaccines and drugs targeting pre-erythrocytic parasite stages in animal models. …”
Get full text

Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon? by Fokas, E, Fokas, E, Liersch, T, Fietkau, R, Hohenberger, W, Hess, C, Becker, H, Sauer, R, Wittekind, C, Rödel, C

“…Downstaging after neoadjuvant treatment is increasingly used as a prognostic factor and surrogate endpoint in clinical trials. However, in recent trials of neoadjuvant 5-fluorouracil-based chemoradiotherapy for rectal cancer, downstaging did not translate into a benefit with regard to either disease-free survival (DFS) or overall survival. …”

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease by Adam S. Fleisher, Michael Donohue, Kewei Chen, James B. Brewer, Paul S. Aisen, the Alzheimer’s Disease Neuroimaging Initiative

“…Magnetic resonance imaging, fluorodeoxyglucose positron emission tomography, new amyloid imaging techniques, and spinal fluid markers of AD all have great potential to provide surrogate endpoint measures for AD pathology. The Alzheimer’s disease neuroimaging initiative (ADNI) was developed for the distinct purpose of evaluating surrogate biomarkers for drug development in AD. …”
Get full text

Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease by Lee E. Neilson, Joseph F. Quinn, Nora E. Gray

“…Peripheral blood mononuclear cells (PBMCs) are an accessible, minimally-invasive source of biomarkers which can be readily assayed and objectively monitored as a surrogate endpoint of NRF2 activation in clinical trials. …”
Get full text

Morning blood pressure surge and arterial stiffness in newly diagnosed hypertensive patients by Ali Kıvrak, Süleyman Özbiçer, Gülhan Yüksel Kalkan, Mustafa Gür

“…Conclusions: We found independent relationship between morning BP surge and arterial stiffness which is a surrogate endpoint for cardiovascular diseases. The inverse relationship between morning BP surge and aortic distensibility and direct relation found in our study is new to the literature.…”
Get full text

Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma by Piotr J. Błoński, Anna M. Czarnecka, Krzysztof Ostaszewski, Anna Szumera-Ciećkiewicz, Piotr Rutkowski

“…Pathological response to neoadjuvant treatment is a biomarker of a favorable prognosis and surrogate endpoint for recurrence-free survival in clinical trials. …”
Get full text

Nasopharyngeal SARS-CoV-2 viral load kinetics using digital PCR by Elizabeth Hastie, Harold Amogan, David Looney, Sanjay R. Mehta

“…Larger studies would be useful to support the use of this measurement as a surrogate endpoint for therapeutic studies.…”
Get full text

Role of In Vitro Tests in the Characterisation of Locally Applied, Locally Acting Drugs in the Throat: Application to Flurbiprofen by Vit Perlik, Hafsa Ali, Jean M. Cardot, Anuradha Kulasekaran

“…Where a validated PD model exists, a comparative clinical study can be performed in healthy subjects; where no surrogate endpoint is available, patients with the relevant indication need to be enrolled, with all the associated factors which could result in lack of sensitivity. …”
Get full text

IgA Nephropathy: What Is New in Treatment Options? by Roberto Scarpioni, Teresa Valsania

“…In the absence of reliable specific biomarkers, current standards of care are addressed to decrease proteinuria, as a surrogate endpoint, and control blood pressure. For a long time, corticosteroids have been considered the only cure for proteinuric patients or those at risk of progression to ESKF; however, unfortunately, like other immunosuppressive agents, they are burdened with high collateral risks. …”
Get full text